Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the Pentavalent Market In 2029?

The market size for pentavalent vaccines has been experiencing consistent growth in the past years. It is projected to increase from a worth of $2.62 billion in 2024 to $2.7 billion in 2025, with a compound annual growth rate (CAGR) of 3.4%. The surge during the historical period can be traced back to factors such as worldwide immunization campaigns, government-sponsored vaccination schemes, multi-disease prevention measures, increasing awareness of public health issues, along with global cooperation and financial backing.

In the coming years, the size of the pentavalent market is predicted to experience consistent expansion. The market is projected to reach $3.24 billion by 2029 with a compound annual growth rate (CAGR) of 4.6%. The anticipated growth within the forecast period is due to ongoing worldwide immunization endeavors, the enlargement of vaccination programs, the market’s entrance into new regions, initiatives in research and development, and partnerships to secure vaccine access. The period is also expected to witness substantial trends such as global health campaigns and financial backing, increased public information and education drives, governmental policies and regulatory structures, along with innovative technological developments in vaccine production.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9104&type=smp

What Are the Core Market Drivers Propelling Growth in the Pentavalent Industry?

The burgeoning incidence of diphtheria is anticipated to propel the expansion of the pentavalent market. Diphtheria, a severe, highly infectious disease, is caused by the Corynebacterium diphtheriae bacterium. The disease, characterized by severe challenges in eating, breathing, and potential skin ulcers, can be prevented in children through pentavalent vaccination administered in a three-dose schedule. As such, the escalating instances of diphtheria have heightened the demand for pentavalent vaccines. For instance, in 2022, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported an unusually high number of diphtheria cases via the International Health Regulations (IHR) reporting process, predominantly during June and August 2022. A total of 144 cases have been recorded across seven nations, a large portion of which were among refugees. Of the 144 cases, 97 (69%) were deemed clinically compatible, 44 (31%) were confirmed as toxigenic diphtheria cases by laboratory confirmation, and 3 (2%) were suspected cases. Consequently, the escalating prevalence of diphtheria continues to stimulate the growth of the pentavalent market.

How Is the Pentavalent Market Segmented?

The pentavalent market covered in this report is segmented –

1) By Type: Sodium Stibogluconate, Meglumine Antimoniate

2) By Formulation Type: Lyophilized, Liquid

3) By Application: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Sodium Stibogluconate: Injectable Form, Oral Form, Other Formulations

2) By Meglumine Antimoniate: Injectable Form, Oral Form, Other Formulations

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=9104&type=smp

Which Regions Are Driving the Next Phase of the Pentavalent Market Growth?

Asia-Pacific was the largest region in the pentavalent market in 2024. The regions covered in the pentavalent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Pentavalent Industry?

The predominant trend being witnessed in the pentavalent market is product innovation. Major players in this market are using the advancement of innovative products as a strategy to consolidate their market presence. A case in point, in December 2022, the US-based pharmaceutical firm, Pfizer, which operates in the pentavalent vaccines market, obtained approval from The United States Food and Drug Administration, a federal agency of the Department of Health and Human Services, for its exploratory Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in adolescents. This is aimed at preventing meningococcal diseases for individuals aged between 10 and 25. The distinctive feature of the MenABCWY vaccine is that it combines the components of two vaccines into one, providing protection against most invasive meningococcal diseases serogroups.

View the full report here:

https://www.thebusinessresearchcompany.com/report/pentavalent-global-market-report

How Is the Pentavalent Market Defined and What Are Its Core Parameters?

Pentavalent refers to a vaccine that protects a child from life-threatening diseases. This vaccine is used to protect infants and young children from rotavirus infection. Rotavirus infection can result in fever, vomiting, and diarrhea.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9104

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model